Hana Magerová

ORCID: 0009-0005-6555-245X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Olfactory and Sensory Function Studies
  • Neurological Disease Mechanisms and Treatments
  • Atrial Fibrillation Management and Outcomes
  • Neurological Disorders and Treatments
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Advanced Chemical Sensor Technologies
  • Acute Ischemic Stroke Management
  • Health, Environment, Cognitive Aging
  • Memory and Neural Mechanisms
  • Biochemical Analysis and Sensing Techniques
  • Functional Brain Connectivity Studies
  • Cerebrovascular and Carotid Artery Diseases
  • Epilepsy research and treatment
  • Historical Studies of British Isles
  • Neurosurgical Procedures and Complications
  • Historical Studies on Reproduction, Gender, Health, and Societal Changes
  • Face Recognition and Perception
  • S100 Proteins and Annexins
  • Diet and metabolism studies
  • Venous Thromboembolism Diagnosis and Management
  • Pharmacogenetics and Drug Metabolism
  • Historical and Cultural Studies of Poland
  • Pharmacological Effects and Toxicity Studies
  • Neurological and metabolic disorders

Charles University
2009-2024

University Hospital in Motol
2009-2024

<i>Background:</i> Patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (MCI) have difficulties spatial orientation. <i>Objective:</i> To test hypothesis that navigation is impaired early in MCI patients representing the presymptomatic stage of AD. <i>Methods:</i> We tested probable AD (n = 21), MCI, further classified according to Petersen’s criteria as (aMCI) single domain 11), aMCI multiple 31), or nonamnestic 7). The group was...

10.1159/000289226 article EN Neurodegenerative Diseases 2010-01-01

Spatial navigation performance in the Hidden Goal Task (HGT), a real-space human analogue of Morris Water Maze, can identify amnestic mild cognitive impairment (aMCI) patients with memory hippocampal type, known indicator incipient Alzheimer's disease (AD).Contrast results from computer versus versions HGT.A total 42 aMCI were clinically and neuropsychologically classified into: (1) type--the (HaMCI; n = 10) (2) isolated retrieval impairment--the nonhippocampal (NHaMCI; 32). Results compared...

10.1159/000333121 article EN Neurodegenerative Diseases 2011-12-23

We examined whether recognition of facial emotional expression would be affected in amnestic mild cognitive impairment (aMCI). A total 50 elderly persons met the initial inclusion criteria; 10 were subsequently excluded (Geriatric Depression Score

10.3233/jad-2012-120148 article EN Journal of Alzheimer s Disease 2012-12-03

Odor identification impairment is a feature of several neurodegenerative disorders. Although changes in the frontotemporal lobar degeneration (FTLD) subtypes involve areas important for olfactory processing, data on function these patients are limited. An 18-item, multiple-choice odor test developed at our memory clinic, Motol Hospital smell test, was administered to 9 with behavioral variant dementia, 13 language variants, primary nonfluent aphasia (n = 7) and semantic dementia 6), 8...

10.1177/1533317514539033 article EN American Journal of Alzheimer s Disease & Other Dementias® 2014-06-16

Variable response after clopidogrel is well documented and may affect major adverse clinical events stroke. Impact of CYP2C19 genetic polymorphisms an established marker linked to variable clopidogrel. However, the association certain with prediction following stroke still remains controversial, especially in Caucasians.The primary aim was evaluate impact allele *2 heterozygote form on Caucasian poststroke survivors treated The secondary analyze potential link between polymorphism...

10.1097/mjt.0000000000000416 article EN American Journal of Therapeutics 2016-04-19

Background:Cerebral microangiopathy in Alzheimer's disease (AD) causes chronic hypoperfusion and probably accelerates neurodegenerative changes. Objective:We hypothesize microvascular impairment could be present already mild cognitive (MCI) can revealed using transcranial color -coded sonography (TCCS) the breath-holding maneuver. Methods:Three groups of subjects (AD stage dementia, MCI, cognitively normal controls) with detailed neuropsychological testing low cerebrovascular burden (no...

10.3233/jad-170815 article EN Journal of Alzheimer s Disease 2018-03-27

This study aimed to evaluate the ability of selected microRNAs as biomarkers atrial fibrillation (AF) in ischemic stroke patients comparison with other established biochemical biomarkers. A prospective case–control consecutive AF admitted a comprehensive center was conducted. The control group consisted no detected on prolonged (at least 3 weeks) Holter ECG monitoring. As potential AF, we analyzed plasma levels (miR-21, miR-29b, miR-133b, miR-142-5p, miR-150, miR-499, and miR-223-3p) 13 at...

10.1097/md.0000000000040165 article EN cc-by-nc Medicine 2024-10-25

APOE ∊4 (∊4) carrier status is a well established risk factor for Alzheimer's disease (AD), interfering with episodic memory and accelerating hippocampal atrophy. Therefore, we hypothesized that hippocampus-specific visual binding test based on the associative learning paradigm can reliably differentiate amnestic mild cognitive impairment (aMCI) carriers from non-carriers. Blood samples were collected to determine genotype. Fifty aMCI patients stratified into aMCI-∊4+ (n=25) aMCI-∊4- groups...

10.1016/j.jalz.2011.05.1525 article EN Alzheimer s & Dementia 2011-07-01

Introduction: Dabigatran is direct thrombin inhibitor approved in the prevention of stroke patients with atrial fibrillation. It was shown RELY trial substudy that genetic variants could contribute to interindividual variability concentrations active metabolite dabigatran and influence safety treatment. Carriage CES1 rs2244613 minor allele associated lower exposure a bleeding risk compared wild-type allele. Aim: To determine gene polymorphism through plasmatic concentration on occurrence...

10.1161/str.49.suppl_1.tmp110 article EN Stroke 2018-01-22

Our goal was to investigate effect of APOE ϵ4 (ϵ4) on spatial working memory (SWM) and attention in amnestic mild cognitive impairment (aMCI) patients assess characteristics the negative (ϵ4-) positive (ϵ4+) aMCI subgroups. A total 58 were stratified according positivity into aMCI-ϵ4- (n=31) aMCI-ϵ4+ (n=27) subgroups compared control AD (n=15) groups. The did not differ basic or any neuropsychological tests. We used Concurrent approach avoid task (CAAT) designed as an analogue Active place...

10.1016/j.jalz.2009.04.1129 article EN Alzheimer s & Dementia 2009-06-25

Ability to recognize facial emotions declines over the course of Alzheimer's disease (AD). The aim our study was determine: 1) how emotion recognition is impaired in relation amygdalar atrophy subjects with amnestic mild cognitive impairment (aMCI) and 2) whether capability identification test might be a profitable tool early diagnosis AD. We examined 23 aMCI further subdivided into multiple domain- aMCImd (n-16), single domain MCI- aMCIsd (n-7) groups 15 age-matched, normal controls (NC)....

10.1016/j.jalz.2010.08.019 article EN Alzheimer s & Dementia 2010-07-01

Článek navazuje na předchozí sdělení tématu tohoto čísla časopisu o ischemických cévních mozkových příhodách (iCMP).Podává přehled antiagregačních a antikoagulačních lécích, které jsou základem sekundární prevence iCMP.Zaměřuje se specifika i nežádoucí účinky jednotlivých léků, výběr vhodné terapie s ohledem etiologii iCMP zmiňuje některé

10.36290/neu.2019.084 article CS Neurologie pro praxi 2019-03-01

The olfactory identificationdysfunction in amnestic mild cognitive impairment (aMCI) which precedes mainly Alzheimer disease (AD) is well known and considered to be caused by AD pathology. presence of non MCI (naMCI) patients with subjective memory complaint (SMC) controversial. aim this study was examine the degree objective dysfunction aMCI, naMCI SMC. 92 aMCI 32 naMCI, 28 SMC 50 age matched healthy controls underwent a multiple choice identification test 18 different odors developed our...

10.1016/j.jalz.2014.05.1262 article EN Alzheimer s & Dementia 2014-07-01

The specific impairment of primacy effect (recall the first words list) has been demonstrated in Alzheimer's disease (AD) and is probably relation with early massive hippocampal involvement this pathology. data on degree recency vascular dementia (VD) are not well known. aim study was to evaluate serial position effects VD patients compare it AD patients. Rey's Auditory Verbal Learning test (RAVLT) administered 32 mild according NINCDS-ADRDA criteria, 28 Vascular NINDS-AIREN criteria 18...

10.1016/j.jalz.2011.05.767 article EN Alzheimer s & Dementia 2011-07-01

Patients with Alzheimer's disease (AD) have smell identification impairment, which occurs in early stages of the and correlates progression. This impairment is attributed to mesiotemporal lobe (MTL) structures atrophy; however accurate anatomical-pathological basis this still unclear. We hypothesize that amygdala atrophy plays a role failure AD its potential prodromal stage - amnestic mild cognitive (aMCI). 18 patients, 30 aMCI patients 11 healthy controls were included study. All subjects...

10.1016/j.jalz.2011.05.474 article EN Alzheimer s & Dementia 2011-07-01

Entorhinal cortex (EC) and hippocampus are impaired very early in the course of Alzheimer's disease (AD). Patients with AD amnestic mild cognitive impairment (aMCI) experience spatial navigation difficulties. Spatial testing human analogue Morris Water Maze (hMWM) can separately examine two types (allocentric vs. egocentric). We hypothesized that patients aMCI would perform worse than normal controls all ocentric-EC hippocampus-dependent subtest inferior parietal cortex-dependent egocentric...

10.1016/j.jalz.2011.05.610 article EN Alzheimer s & Dementia 2011-07-01

Our previous published results indicated that spatial navigation testing in the real-space human analogue of Morris Water Maze (MWM) can distinguish amnestic mild cognitive impairment (aMCI) patients with (versus without) hippocampus-related memory impairment, hence offering a tool to identify cases susceptible for conversion Alzheimer's disease (AD). We contrasted from computer version MWM test itself and tested whether it also discriminate two different aMCI groups. A total 42 were...

10.1016/j.jalz.2010.05.1192 article EN Alzheimer s & Dementia 2010-07-01

Ability to recognize facial emotions declines over the course of Alzheimer's disease (AD). The aim our study was determine: 1) how emotion recognition is impaired in relation amygdalar atrophy subjects with amnestic mild cognitive impairment (aMCI) and 2) whether capability identification test might be a profitable tool early diagnosis AD. We examined 23 aMCI further subdivided into multiple domain- aMCImd (n-16), single domain MCI- aMCIsd (n-7) groups 15 age-matched, normal controls (NC)....

10.1016/j.jalz.2010.05.953 article EN Alzheimer s & Dementia 2010-07-01

The olfactory identification impairment in amnestic mild cognitive (aMCI) which precedes mainly Alzheimer disease (AD) is well known and considered to be caused by AD pathology. degree of nonamnestic MCI (naMCI), converts non-Alzheimer's types dementia, less known. There little information whether the deficit perceived patients. aim this study was examine objective subjective dysfunction naMCI compare it aMCI. 89 patients with aMCI 29 according Peterson's criteria 49 age-matched healthy...

10.1016/j.jalz.2012.05.1316 article EN Alzheimer s & Dementia 2012-07-01

Mild cognitive impairment (MCI) is a clinical entity insufficiently severe to be classified as dementia, when subjects maintain their functional capacity. Several longitudinal studies have suggested that with amnestic MCI multiple domain higher rate of progression dementia during the follow-up period. Neuroimaging and neuropathological in isolated memory demonsrated an atrophy pathological changes amygdala, structure plays important role facial expression processing well emotional...

10.1016/j.jalz.2010.05.1183 article EN Alzheimer s & Dementia 2010-07-01
Coming Soon ...